La néphrectomie est-elle indispensable en cas de métastases ?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progres En Urologie

• Publication date

  2010-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S1166-7087(10)70023-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response

  2008cited by this paper
• Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

  2008cited by this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma

  2008cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

  2005influential reference
• Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy

  2004cited by this paper
• Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

  2003cited by this paper
• The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.

  2003cited by this paper
• Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.

  2002cited by this paper
• The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy.

  2002cited by this paper
• Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

  2001cited by this paper
• Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

  2001cited by this paper
• Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.

  2001cited by this paper
• Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.

  2000cited by this paper
• Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy.

  2000cited by this paper
• Urothelial cancer--mucosally confined disease can be aggressive.

  2000cited by this paper
• Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.

  1999cited by this paper
• Resection of metastatic renal cell carcinoma.

  1998cited by this paper
• Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.

  1998cited by this paper
• Increased Transforming Growth Factor β1 Plasma Level in Patients with Renal Cell Carcinoma:A Tumor-Specific Marker?

  1998cited by this paper
• Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

  1997influential reference
• Cytoreductive surgery for stage IV renal cell carcinoma.

  1995cited by this paper
• Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.

  1995cited by this paper
• Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy.

  1994cited by this paper
• Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.

  1993cited by this paper
• Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

  1992cited by this paper
• Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.

  1989cited by this paper
• Spontaneous regression of metastatic renal cell carcinoma.

  1982cited by this paper
• The natural history of metastatic renal cell carcinoma: a computer analysis.

  1978cited by this paper
• Idiopathic regression of metastases from renal cell carcinoma.

  1977cited by this paper

• Quelles complications péri-opératoires ?

  2011cites this paper
• Cas cliniques de cancer du rein des JOUM 2010.

  2011cites this paper